端粒缩短与慢性髓性白血病诊断时白血病干细胞负荷相关
该研究比较了慢性髓性白血病(CML)患者诊断时骨髓中BCR-ABL阴性非白血病CD34+CD38-造血干细胞(HSC)与对应BCR-ABL阳性白血病干细胞(LSC)的端粒长度(TL),发现LSC端粒缩短显著加速且缩短程度与白血病克隆大小显著相关;EURO-SKI研究(NCT01596114)中134份深度分子学缓解期外周血样本显示粒细胞端粒长度与年龄匹配对照队列相比无显著缩短。
要点
- CML诊断时LSC端粒缩短较非白血病HSC显著加速。
- LSC端粒缩短程度与白血病克隆大小显著相关。
- 长期TKI治疗后非白血病髓系细胞端粒长度似乎不受影响。
核心结论
- 本研究为CML诊断时LSC相对于HSC的端粒缩短加速提供了原理验证。
- 端粒缩短程度与白血病克隆大小相关,支持将白血病细胞端粒长度作为预后参数,但有待前瞻性验证。
- 非白血病髓系细胞端粒长度似乎不受长期TKI治疗影响,提示TKI治疗下正常造血中端粒介导的复制储备未见减少。
研究设计与样本
- 比较CML患者诊断时骨髓中BCR-ABL阴性非白血病CD34+CD38- HSC与对应BCR-ABL阳性LSC的端粒长度。
- 在EURO-SKI研究(NCT01596114)中前瞻性评估TKI治疗后深度分子学缓解期采集的134份外周血样本的端粒长度。
主要发现
- LSC端粒缩短较非白血病HSC显著加速。
- LSC端粒缩短程度与白血病克隆大小显著相关。
- EURO-SKI研究中134份深度分子学缓解期外周血样本的粒细胞端粒长度与年龄匹配对照队列相比无显著缩短。
局限性
- 原文指出端粒长度因个体间遗传变异大而差异显著,限制了其作为单个患者稳健预后标志物的应用。
- 原文结论提出将白血病细胞端粒长度作为预后参数有待前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Telomere length (TL) in peripheral blood (PB) cells of patients with chronic myeloid leukemia (CML) has been shown to correlate with disease stage, prognostic scores, response to therapy, and disease progression. However, due to considerable genetic interindividual variability, TL varies substantially between individuals, limiting its use as a robust prognostic marker in individual patients. Here, we compared TL of BCR-ABL-, nonleukemic CD34+CD38- hematopoietic stem cells (HSC) in the bone marrow of CML patients at diagnosis to their individual BCR-ABL+ leukemic stem cell (LSC) counterparts. We observed significantly accelerated telomere shortening in LSC compared with nonleukemic HSC. Interestingly, the degree of LSC telomere shortening was found to correlate significantly with the leukemic clone size. To validate the diagnostic value of nonleukemic cells as internal controls and to rule out effects of tyrosine kinase inhibitor (TKI) treatment on these nontarget cells, we prospectively assessed TL in 134 PB samples collected in deep molecular remission after TKI treatment within the EURO-SKI study (NCT01596114). Here, no significant telomere shortening was observed in granulocytes compared with an age-adjusted control cohort. In conclusion, this study provides proof of principle for accelerated telomere shortening in LSC as opposed to HSC in CML patients at diagnosis. The fact that the degree of telomere shortening correlates with leukemic clone's size supports the use of TL in leukemic cells as a prognostic parameter pending prospective validation. TL in nonleukemic myeloid cells seems unaffected even by long-term TKI treatment arguing against a reduction of telomere-mediated replicative reserve in normal hematopoiesis under TKI treatment.
引用
- Bouillon AS, Ventura Ferreira MS, Awad SA, et al. Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia. Blood Adv. 2018. PMID: 29980572. doi:10.1182/bloodadvances.2018017772
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。